[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
    "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
    "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758142593,
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "id": 136791560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
      "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating “its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies.” The results showed that both trials met their respective primary and […]",
    "url": "https://finnhub.io/api/news?id=953ccf917811ba01e7fc5171ccd2b9b9f22e565c0d1dacb93c827823d3e8a311",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758137223,
      "headline": "Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies",
      "id": 136791735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating “its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-severe cat or birch allergies.” The results showed that both trials met their respective primary and […]",
      "url": "https://finnhub.io/api/news?id=953ccf917811ba01e7fc5171ccd2b9b9f22e565c0d1dacb93c827823d3e8a311"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Says Antibody Combo May Preserve Muscle During Weight Loss",
    "summary": "Regeneron Pharmaceuticals (REGN) said Wednesday updated Phase 2 trial results suggest that combining",
    "url": "https://finnhub.io/api/news?id=d5a5e4dcb8b7bcc111a1c042c3307bfee4b30db99f9692071b850c96b444067b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758123357,
      "headline": "Regeneron Says Antibody Combo May Preserve Muscle During Weight Loss",
      "id": 136789496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) said Wednesday updated Phase 2 trial results suggest that combining",
      "url": "https://finnhub.io/api/news?id=d5a5e4dcb8b7bcc111a1c042c3307bfee4b30db99f9692071b850c96b444067b"
    }
  },
  {
    "ts": null,
    "headline": "Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD",
    "summary": "Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss Numeric improvements in metabolic and lipid parameters including waist circumference, blood pressure, cholesterol, triglycerides and A1C, were observed across all treatment groups TARRYTOWN, N.Y., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today",
    "url": "https://finnhub.io/api/news?id=5c2c1707ef1400bdf5c454e21fa9af7ea6bbf0c1e7e1b006ca93f97bcd8f2904",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119400,
      "headline": "Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD",
      "id": 136789120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss Numeric improvements in metabolic and lipid parameters including waist circumference, blood pressure, cholesterol, triglycerides and A1C, were observed across all treatment groups TARRYTOWN, N.Y., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today",
      "url": "https://finnhub.io/api/news?id=5c2c1707ef1400bdf5c454e21fa9af7ea6bbf0c1e7e1b006ca93f97bcd8f2904"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation",
    "summary": "FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both number and volume of abnormal bone lesions (heterotopic ossification, or HO lesions) in adults with FOP Primary endpoint was met, showing a 90% or greater reduction in new HO lesions at 56 weeks, and garetosmab also led to a greater than 99% reduction in the total volume of new HO les",
    "url": "https://finnhub.io/api/news?id=5be5bf896d95575857de9b3d74d1ec95ed1775825f0177890be36faf2e72236f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758110400,
      "headline": "Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation",
      "id": 136787680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic reduction in both number and volume of abnormal bone lesions (heterotopic ossification, or HO lesions) in adults with FOP Primary endpoint was met, showing a 90% or greater reduction in new HO lesions at 56 weeks, and garetosmab also led to a greater than 99% reduction in the total volume of new HO les",
      "url": "https://finnhub.io/api/news?id=5be5bf896d95575857de9b3d74d1ec95ed1775825f0177890be36faf2e72236f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass",
    "summary": "Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass",
    "url": "https://finnhub.io/api/news?id=5a0cd25a7a5fb539facb1a5f7f3336eb71ad49752b063997994d153de14dec39",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758104100,
      "headline": "Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass",
      "id": 136872929,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass",
      "url": "https://finnhub.io/api/news?id=5a0cd25a7a5fb539facb1a5f7f3336eb71ad49752b063997994d153de14dec39"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study",
    "summary": "Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study",
    "url": "https://finnhub.io/api/news?id=65416becb687a934733471935493a1e942c438edae4a948b03d98f9319344fc3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758093780,
      "headline": "Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study",
      "id": 136872930,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study",
      "url": "https://finnhub.io/api/news?id=65416becb687a934733471935493a1e942c438edae4a948b03d98f9319344fc3"
    }
  }
]